Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data ...

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm PharmaceuticalsRYTM shares surged to a record high Wednesday on promising results for a drug that could treat a rare ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% higher in ...

Rhythm Pharmaceuticals, Inc. (RYTM) on Wednesday announced that its drug Bivamelagon achieved statistically significant and ...

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Rhythm Pharmaceuticals has captured Wall Street's attention following impressive Phase 2 results for its experimental obesity ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

Rhythm estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S., 5,000 to 8,000 people living with hypothalamic obesity in Japan, and 3,500 to 10,000 people living ...

Rhythm said results of the recent trial were also consistent with BMI reductions achieved with setmelanotide therapy in similar patient populations in past trials. Setmelanotide, an existing ...